Literature DB >> 1866569

Diagnosis and pathogenesis of CNS lupus.

A P van Dam1.   

Abstract

The central nervous system (CNS) is clinically involved in approximately 40% of all systemic lupus erythematosis (SLE) patients. Minor psychiatric symptoms and abnormalities on neuropsychological testing are being detected with increasing frequency. This review summarizes current thinking concerning the diagnosis and pathogenesis of CNS lupus. The main symptoms of CNS lupus can be diffuse (generalized seizures, psychosis) or focal (stroke, peripheral neuropathies). Neuropsychiatric symptoms often occur in the first year of SLE, but are rarely the presenting symptoms of the disease. In studies on the pathology of CNS lupus, vasculopathy, infarcts and haemorrhages are often observed, whereas vasculitis is rare. Endocardial lesions and mural thrombi have also been reported in 33-50% of CNS lupus patients. In diagnostic imaging of the CNS, magnetic resonance imaging (MRI) scans often provide evidence for edema or small infarcts, both in focal and diffuse CNS lupus, whereas computerized tomography (CT) scans only show gross abnormalities. The first reports on position emission tomography (PET) scans in CNS lupus patients show decreased glucose uptake in the brain. The cerebral blood flow decreases during active diffuse and focal CNS lupus. The blood-brain barrier is somewhat more frequently impaired in diffuse CNS lupus. Intrathecal IgG and IgM production is observed in 25-66% of all CNS lupus patient. Various specificities of autoantibodies have been observed in CNS lupus. Of these, anticardiolipin (ACA) antibodies show a well-documented association with focal involvement of the CNS in SLE. These antibodies could cause thrombosis by interfering with the protein C pathway of fibrinolysis. In addition, they are associated with endocardial and valvular heart disease, which is often observed in SLE and which could cause embolism. The relation between ACA and diffuse CNS lupus is not yet clear. Low-avidity anti-DNA antibodies are also found in CNS lupus, possibly because of their cross-reaction with cardiolipin. Antineuronal antibodies and lymphocytotoxic antibodies have been associated with diffuse CNS lupus and abnormalities on neuropsychological testing. However, the population of these antibodies is rather heterogeneous and it has not been possible to assess a common target antigen. Therefore, it is still obscure whether there is also a second immune-mediated mechanism responsible for the development of the diffuse form of CNS lupus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1866569     DOI: 10.1007/bf00290244

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  91 in total

1.  CLINICAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. COMPUTER ANALYSIS OF 520 CASES.

Authors:  E L DUBOIS; D L TUFFANELLI
Journal:  JAMA       Date:  1964-10-12       Impact factor: 56.272

2.  Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant.

Authors:  E Marciniak; E H Romond
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

Review 3.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

4.  Lupus anticoagulant, antiphospholipid antibodies and migraine.

Authors:  M J Hogan; D G Brunet; P M Ford; D Lillicrap
Journal:  Can J Neurol Sci       Date:  1988-11       Impact factor: 2.104

5.  Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus.

Authors:  Y Ishii; K Nagasawa; T Mayumi; Y Niho
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

6.  Low avidity antibodies to dsDNA as a diagnostic tool.

Authors:  J C Nossent; V Huysen; R J Smeenk; A J Swaak
Journal:  Ann Rheum Dis       Date:  1989-09       Impact factor: 19.103

7.  Anticardiolipin antibodies in patients with systemic lupus erythematosus.

Authors:  G Sturfelt; O Nived; R Norberg; R Thorstensson; K Krook
Journal:  Arthritis Rheum       Date:  1987-04

8.  Cerebrospinal fluid IgM, IgA, and IgG indexes in systemic lupus erythematosus. Their use as estimates of central nervous system disease activity.

Authors:  S Hirohata; S Hirose; T Miyamoto
Journal:  Arch Intern Med       Date:  1985-10

9.  Failure to detect brain reactivity of lymphocytotoxins in cerebral lupus.

Authors:  B A Pussell; F Blyth; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

10.  Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets.

Authors:  M C Hochberg; R E Boyd; J M Ahearn; F C Arnett; W B Bias; T T Provost; M B Stevens
Journal:  Medicine (Baltimore)       Date:  1985-09       Impact factor: 1.889

View more
  27 in total

1.  Cerebral leucocyte infiltration in lupus-prone MRL/MpJ-fas lpr mice--roles of intercellular adhesion molecule-1 and P-selectin.

Authors:  W G James; P Hutchinson; D C Bullard; M J Hickey
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  Neuroimmunopathology in a murine model of neuropsychiatric lupus.

Authors:  David A Ballok
Journal:  Brain Res Rev       Date:  2006-12-20

3.  Microglia-dependent synapse loss in type I interferon-mediated lupus.

Authors:  Allison R Bialas; Jessy Presumey; Abhishek Das; Cees E van der Poel; Peter H Lapchak; Luka Mesin; Gabriel Victora; George C Tsokos; Christian Mawrin; Ronald Herbst; Michael C Carroll
Journal:  Nature       Date:  2017-06-14       Impact factor: 49.962

4.  Very severe amnesia with acute onset after isolated hippocampal damage due to systemic lupus erythematosus.

Authors:  A Schnider; C Bassetti; A Schnider; K Gutbrod; C Ozdoba
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

5.  Hemichorea with antiphospholipid antibodies in a patient with systemic lupus erythematosus.

Authors:  Ana Vide Brochado; Sofia Pimenta; Marta Silva; Raquel Sousa; Maria Manuel Campos; Iva Brito
Journal:  BMJ Case Rep       Date:  2009-08-19

6.  A case of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with lupus erythematosus in the central nervous system.

Authors:  Hiroaki Hara; Hajime Hasegawa; Mizuki Iwanaga; Tomonya Ogawa; Akihiko Matsuda; Koichi Kanozawa; Hitoshi Kato; Tetsuya Mitarai
Journal:  CEN Case Rep       Date:  2012-08-15

Review 7.  Cognitive and emotional abnormalities in systemic lupus erythematosus: evidence for amygdala dysfunction.

Authors:  Philip Watson; Justin Storbeck; Paul Mattis; Meggan Mackay
Journal:  Neuropsychol Rev       Date:  2012-08-11       Impact factor: 7.444

8.  Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report.

Authors:  F Y Liu; W S Huang; C H Kao; R F Yen; J J Wang; S T Ho
Journal:  Rheumatol Int       Date:  2003-01-30       Impact factor: 2.631

9.  Recurrent opticomyelitis associated with anti-DNA antibody.

Authors:  J Kira; I Goto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

10.  Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate.

Authors:  G Valesini; R Priori; A Francia; G Balestrieri; A Tincani; P Airo; R Cattaneo; A Zambruni; B Troianello; M Chofflon
Journal:  Springer Semin Immunopathol       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.